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Cisplatin-based chemotherapy of malignant germ cell tumours (MGCT) has been reported to increase the risk of cardiovascular
morbidity. A high incidence of second nongerm cell malignancies is well documented in MGCT survivors. The death risk due to these
conditions is, however, more unknown in MGCT patients. Standard mortality rates (SMRs) were established in 3378 Norwegian
MGCT patients treated from 1962 to 1997 aged p55 years. The patients represented three principal treatment strategies: 1962/
1969 (period 1): radiotherapy only; 1970/1979 (period 2): radiotherapy with or without noncisplatin-containing chemotherapy; 1980/
1997 (period 3): surgery only or radiotherapy or cisplatin-based chemotherapy. Patients were censored when they reached the age
of 60 years. Patients not dying from MGCT displayed significantly increased SMRs for respectively diseases of the circulatory system
(SMR: 1.2, 95% confidence interval (CI): 1.0–1.5), benign gastrointestinal disorders (SMR: 2.1, 95% CI: 1.1–3.5) and nongerm cell
malignancies (SMR: 2.0, 95% CI: 1.7–2.4). The SMRs for diseases of the circulatory system were similar in the three observation
periods, whereas the highest SMR for benign gastrointestinal disorders was observed in patients from period 2. The risk of dying from
a nongerm cell malignancy was increased both in periods 2 and 3. In conclusion, although the overall SMR for diseases of the
circulatory system is increased in MCGT survivors, the introduction of cisplatin-based chemotherapy into the treatment of MGCT has
so far not resulted in increased death rates due to these conditions. Patients with MGCT have a significantly increased relative death
risk due to a second nongerm cell cancer, even after the introduction of modern treatment principles with overall reduction of
radiotherapy. The increased death risk due to benign gastrointestinal disorders, probably related to radiotherapy, requires future in-
depth analysis.
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Malignant germ cell tumours (MGCT), about 95% of them being
testicular cancer, represent the most frequent malignancy in men
aged 20–34 years (Engeland et al, 1993), and the incidence is
rising. For many years radiotherapy has been the cornerstone in
the treatment of testicular seminoma, and X98% of the patients
become long-term survivors (Fossa ˚ et al, 1999). Although the
surveillance policy has been introduced into the treatment of
seminoma (Warde et al, 2002), adjuvant radiotherapy will world-
wide continue to be the standard treatment in many countries
where adequate and frequent follow-up of the patients is not
feasible. After the introduction of cisplatin-based therapy in the
1970s, about 90% of the patients with nonseminoma are cured.
This implies that most patients with MGCT theoretically have a life
expectancy of 30–50 years after their successful treatment. It is,
however, known from single institution studies and from large
cancer registry-based reports that testicular cancer survivors have
an increased incidence of second cancer (van Leeuwen et al, 1993;
Hoff Wandera ˚s et al, 1997; Travis et al, 1997, 2000). The increase
has been most pronounced for sarcoma, malignancies of the
gastrointestinal tract, lung cancer and for bladder cancer. These
solid cancers develop mostly 10 years or more after radiotherapy,
when patients are no longer followed up intensively by their
primarily responsible oncological unit. Epidemiologically less
established are observations on late adverse events related to
obesity, hypercholesterolaemia and decreased kidney function and
to cardiovascular events (Hansen et al, 1988; Ellis et al, 1992;
Raghavan et al, 1992; Bokemeyer et al, 1996; Fossa ˚ et al, 1989;
Meinardi et al, 2000; Huddart et al, 2003; Fossa ˚ et al, 2003; Nord
et al, 2003a). Single-centre reports have indicated that such
conditions may be associated with the modern treatment of
MGCT, in particular with the use of cisplatin-based chemotherapy.
Late cardiac complications are, however, also described after
mediastinal irradiation (Lederman et al, 1987), a common
adjuvant treatment strategy before 1980 in seminoma patients.
Furthermore, the possibility exists that the development of
cardiovascular diseases in patients with MGCT is related to the
disease itself, for example mediated by the relative hypogonadism,
observed in 10–15% of the patients (Petersen et al, 1998; Nord
et al, 2003b).
There is no doubt that moderate dosed radiotherapy as applied
today in MGCT may lead to a slight degree of gastrointestinal
dysfunction and peptic ulcers in 3–10% of the cases (Fossa ˚ et al,
1989; Yeoh et al, 1995). The occurrence of more severe
gastrointestinal disorders is rare, but severe and even lethal
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lcomplications have been described many years after the combina-
tion of radiotherapy and chemotherapy. This combination is still
valid for irradiated patients with seminoma, developing a relapse.
Although the incidence of second malignancies (van Leeuwen
et al, 1993; Hoff Wandera ˚s et al, 1997; Travis et al, 1997, 2000) in
relation to the patient’s primary treatment and the occurrence of
gastrointestinal of cardiovascular disorders (Fossa ˚ et al, 1989;
Yeoh et al, 1995) after chemotherapy have been described in
several reports, much less is known about the causes of death in
patients who are successfully treated for MGCT. Large epidemio-
logical studies are lacking, which prove any relation between
different treatment modalities of MGCT and late nonmalignant
complications. One reason for the lack of such large-scale data is
the fact that only few countries have population-based registries
for gastrointestinal or cardiovascular disorders, which can be used
for comparison. In this situation, the analysis of mortality data
may increase the understanding of any relation between the
treatment of MGCT and the development of subsequent lethal, but
benign disorders. Although such an analysis per se must be
retrospective and is largely based on treatments no longer relevant
for MGCT, many patients with MGCT treated according to ‘old-
fashioned’ strategies are still alive and at risk to develop serious
complications often 15–20 years after their treatment. Further-
more, the results obtained in patients with MGCT as to late
treatment-related mortality may be relevant for the oncological
therapy of solid malignancies in general.
From a clinical point of view, one would expect increased
mortality rates due to second nongerm cell malignancies, as most
of these are cancer types with a generally poor prognosis. It is,
however, more uncertain as to whether a high incidence of
cardiovascular morbidity among MGCT patients, if at all present,
corresponds with a raised mortality rates due to diseases of the
circulatory system. With this background, the primary aim of the
present study is to present mortality rates for diseases of the
circulatory system among MGCT survivors compared with
comparable rates in the age-matched male population. We also
include the analysis of death rates from nongerm cell cancer, and
from selected nonmalignant diseases among the same patients.
PATIENTS AND METHODS
Cancer reporting to the Cancer Registry of Norway (NCR) has been
compulsory since the registration started in 1953. All hospitals and
histopathological laboratories are committed independently to
report all new cases of cancer, also subsequent primary cancers,
including information at the time of diagnosis and extent of the
disease. The latter is categorised as locally confined, regionally
advanced or distant metastatic. The registration of basal cell
carcinoma has not been quality-secured, and these cancer cases are
excluded from the present analysis. All death certificates are coded
by Statistics Norway and linked to the NCR through the unique
personal identification number given to every citizen in Norway.
This linkage provides the information on the date and cause of
death. All patients were followed up with respect to cause of death
until the end of 1997.
The NCR is incomplete as to the primary treatment of cancer
patients and their clinical follow-up. Therefore, the patients were
grouped into three cohorts based on the year of diagnosis of
MGCT:
NCR-1: diagnosed between 1962 and 1969 (period 1)
NCR-2: diagnosed between 1970 and 1979 (period 2)
NCR-3: diagnosed between 1980 and 1997 (period 3)
These time intervals mirror major changes in the postorchiect-
omy treatment principles of Norwegian TC patients: nearly all
patients from the NCR-1 group were treated with high-voltage
radiotherapy alone. Nonmetastatic patients with seminoma or
nonseminoma underwent infradiaphragmatic radiotherapy, re-
spectively, 40 and 50Gy, whereas patients with metastases had
mediastinal irradiation and/or palliative limited field radiotherapy.
Chemotherapy was not used in general, and, if given, cyclopho-
sphamide was the only available drug before 1971. Nonmetastatic
patients from the NCR-2 group were treated similarly to those
from the NCR-1 group, while metastatic patients received available
chemotherapy (cyclophosphamide, mitomycin, actinomycin D,
adriamycin, bleomycin, vinblastine, metothrexate) in combination
with abdominal and mediastinal irradiation. From 1980 (NCR-3
group), cisplatin-based chemotherapy represented the standard
treatment for patients with metastatic nonseminomatous MGCT.
Nonmetastatic patients with nonseminoma underwent retroper-
itoneal lymph node dissection (RPLND) or were included into a
surveillance programme (from 1989). Adjuvant abdominal radio-
therapy was restricted to seminoma patients without metastases,
the target dose being p30Gy in most patients. The use of
prophylactic mediastinal irradiation was discontinued. During the
early 1980s, patients with metastatic seminoma received post-
chemotherapy radiotherapy to residual masses. This policy was
gradually abandoned after 1985.
Of all TC patients, 9% were older than 55 years of age at the time
of diagnosis. These patients were excluded from all analyses to
avoid a group of men having a considerable risk of diseases of the
circulatory system, a priori probably not related to their TC. Due
to this high incidence of circulatory disorders in elderly men of the
general population, any existing but presumably small difference
would remain undetectable. Due to the same reason, patients were
censored in the analysis when they reached the age of 60 years (all
together 122 patients).
The observed number of deaths from a specified condition was
compared with the expected number of deaths estimated by applying
the specific mortality rates for 1-year age groups and 1-year birth
years in the MGCT-patient group under consideration. Based on the
observed (OBS) and expected (EXP) numbers of deaths, standar-
dised mortality ratios (SMRs) were calculated. The absolute excess
risk (AER) is calculated by the difference between the observed and
expected numbers of deaths divided by the number of person years
and multiplied by 10000. The estimated 95% confidence intervals
(95% CI) for both SMR and AER were based on the assumption that
the observed numbers were Poisson distributed.
RESULTS
The series comprises 3378 patients representing 41960 patients
years. The distribution of seminoma vs nonseminoma was about
1:1. Distribution of the extent of the disease at the time of diagnosis
was similar in the three groups. In spite of an increasing incidence of
MGCT, the overall mortality in these patients (all causes included)
has decreased dramatically after 1980, when cisplatin became
available for the treatment of Norwegian TC patients (Figure 1).
The main cause of death was, of course, MGCT with 493 out of
609 cancer deaths. A total of 116 patients died from other types of
cancer, which gave an SMR of 2.0 (95% CI: 1.7–2.4) (Table 1). The
relative risk rates of dying from nongerm cell cancer were lowest
during period 1 with significantly raised SMRs in patients treated
during periods 2 and 3. Standard mortality rates were significantly
increased for stomach, pancreatic and lung cancer, in particular in
patients from the NCR-2 group. These relative risk rates are
associated with significantly raised figures of AER.
A total of 181 TC patients died from benign conditions, while
163 deaths were expected (SMR: 1.1; 95% CI: 0.95–1.27). All
patients combined displayed a slight, although significantly
increased relative risk of dying from diseases of the circulatory
system (ICD-9: 390–458), the SMR being 1.2 (95% CI: 1.0–1.5),
with a nonsignificantly increased risk of dying from myocardial
infarction (ICD-9: 410–414), the SMR being 1.1 (95% CI: 0.9–1.4)
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the risk of dying from circulatory disorders was, however, not
significantly increased. Neither was there a change of these
mortality rates comparing the three time periods with each other.
Notably, the relative risk of dying from diseases of the circulatory
system has so far remained unchanged after the introduction of
cisplatin-based chemotherapy into the treatment of MGCT.
Neither do the figures for AER mirror an increased risk of
cardiovascular death during the third period, although the
respective CIs were wide and overlapping, without reaching the
level of statistical significance.
The SMR and AER for benign gastrointestinal disorders (ICD-9:
520–577) were significantly increased for the three diagnostic
periods combined with a particular increase within the NCR-2
group when the combination of chemotherapy containing
adriamycin and actinomycin D, with radiotherapy had gained
some popularity. The 14 deaths were due to liver cirrhosis or
unspecified liver diseases (six patients), cholelithiasis (two
patients), acute vascular disorders of the gastrointestinal tractus
(two patients), oesophago-gastro-duodenal ulcus (two patients),
peritonitis (one patient) and appendicitis (one patient). All but two
of these patients had had infra-diaphragmatic radiotherapy from 6
to 22 years prior to death. In all, 34 MGCT patients died from
accidents, poisoning or suicide. This number did not significantly
deviate from 40.1 cases expected in the general population.
DISCUSSION
This report documents an increased risk for cured MGCT patients
to die from nongerm cell cancer, from diseases of the circulatory
system and from benign gastrointestinal disorders. No obvious
differences as to the period of treatment were observed for the risk
of dying from circulatory disorders. The combination of radio-
therapy with noncisplatin-containing chemotherapy (NCR-2
group) represented a particularly high risk of dying from benign
gastrointestinal disorders. As expected, the increasing use of
cytostatics, especially if combined with radiotherapy (period 2),
increased the death rate due to a second nongerm cell cancer.
Based on long-term studies, often performed in more limited
series of testicular cancer survivors, several investigators have
reported an increased prevalence of cardiovascular risk factors and
disorders of the circulatory system in MGCT patients after curative
cisplatin-based chemotherapy (Bokemeyer et al, 1996; Meinardi
et al, 2000; Huddart et al, 2003). After such cytostatic treatment,
patients more often had increased serum levels of cholesterol,
weight gain, hypertension and decreased renal function (Hansen
et al, 1988; Ellis et al, 1992; Raghavan et al, 1992; Bokemeyer et al,
1996; Nord et al, 2003a) than the age-matched general population,
or compared to MGCT patients treated by surgery only. Our data
support the view of increase of diseases of the circulatory system in
patients with MGCT, as our complete cohort of MGCT patients
indeed displayed a marginally increased risk of dying from
circulatory diseases (SMR: 1.2 (95% CI: 1.0–1.5)). Based on the
above literature, we had expected particularly increased mortality
rates due to cardiovascular disorders after the introduction of
cisplatin-based chemotherapy in 1980 (NCR-3 group), but so far
we have been unable to document such figures. If one accepts the
association between the year of diagnosis and treatment, as
described in the section of Patients and methods, and the
limitation of a short follow-up period for the third group, the
death risk due to circulatory disorders, including myocardial
infarction, was not related to the use of cisplatin-based
chemotherapy . No increased risk was seen in the patients from
the NCR-3 group; about 40% of them had been treated with
cisplatin-based chemotherapy and only exceptionally combined
with radiotherapy. Several reasons may explain the lack of the
expected elevated postchemotherapy risk of cardiovascular deaths
in the third period. Cardiac irradiation in patients without
chemotherapy may be a confounding factor, reducing any existing
intergroup difference: even after 1980, the routine target radiation
field in patients with early testicular cancer includes the lower part
of the heart, generally resulting in radiation doses of 30–90cgy of
the whole heart or parts of it (Huddart et al, 2003). Furthermore,
during the first two periods of our study, patients with lymph node
metastases had mediastinal radiotherapy at doses of 40–45Gy,
including major parts of the heart. From the experience in patients
with Hodgkin’s disease (Glanzmann et al, 1998), it is known that
mediastinal radiotherapy increases the risk of subsequent cardi-
omyopathy. Furthermore, older drugs used in the treatment of
advanced testicular cancer before 1980, such as Actinomycin D or
Adriamycin may have enhanced such radiation effect or are
cardiotoxic by themselves.
Our data on mortality rates due to circulatory disorders do not,
however, completely exclude the possibility of an increased risk of
dying from cardiovascular diseases related in particular to
cisplatin-based chemotherapy of MGCT, as our follow-up ends
in 1997, only 17 years after the introduction of cisplatin in the
treatment of MGCT. Longer follow-up may change the shown
pattern of mortality risks. We can neither exclude the possibility
that cisplatin-based chemotherapy is related to an increased risk of
cardiovascular morbidity. During the 1980s and 1990s, improved
treatment of hypertension and hyperlipidaemia and more success-
ful management of myocardial infarction may have led to reduced
mortality rates due to circulatory diseases, in spite of persistent or
even increasing morbidity rates (Molstad and Andersen, 2002).
Regrettably, no Norwegian national population-based registries are
available on diseases of the circulatory system, which could prove
this hypothesis of increasing morbidity and decreasing mortality.
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Figure 1 Age-adjusted (Based on World Standard population) incidence
(A) and mortality (B) rates for patients with malignant germ cell tumours
diagnosed from 1965 to 1999 (The Cancer Registry of Norway, personal
communication, 2002).
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causes leading to cardiovascular events and high-risk factors in
testicular cancer survivors. Slight hypogonadism as reduced
testosterone serum levels and/or increased LH serum levels are
seen in about 15% of these patients (Huddart et al, 2003; Nord et al,
2003a). Hypogonadism may by itself lead to premature ageing with
its consequences on disorders of the circulatory system, including
increased BMI, serum lipid disturbances and hypertension. Future
comparative long-term studies in patients treated after 1980 and
following modern treatment strategies have to further clarify the
impact of cisplatin-based chemotherapy or of other factors on the
development of cardiovascular disorders.
A completely unexpected observation was the significantly
raised death rate due to benign gastrointestinal disorders.
Abdominal radiotherapy at doses of 40–50Gy, in particular if
combined with chemotherapy seems to contribute considerably to
this risk, especially in patients treated before cisplatin became
available in Norway (period 2). This is in agreement with our
previous observations of increased gastrointestinal morbidity after
radiotherapy alone or after the combination of abdominal radio-
therapy with adriamycin-containing chemotherapy (Fossa ˚ et al,
1989; Hoff Wandera ˚s et al, 1994). Our findings also show that
gastro-duodenal ulcer, recognised as radiotherapy-induced long-
term toxicity (Fossa ˚ et al, 1989), not only represents a significant
morbidity but may also be the patient’s cause of death. This
observation is in contrast to Horwich and Bell’s (1994) report, who
did not find an excess of the death rate of benign disorders after
radiotherapy for seminoma. The high SMR due to disorders of the
liver or its excretory duct system was surprising and requires a
future in-depth analysis. At the present time, we propose the
following explanation: Fibrosis is a well-known dose-dependent
late side effect of radiotherapy, although its development only
rarely causes clinical symptoms in testicular cancer survivors.
However, retroperitoneal fibrosis may exceptionally cause stenoses
of the ureteres and/or of the bile or hepatic ducts (Moul, 1992;
Biermann et al, 1994) 6–20 years after radiotherapy. The fibrotic
changes in the upper retroperitoneal space may even mimic
pancreatic cancer (Stensvold et al, 2003). In rats, whole-liver
radiation with 24Gy resulted in significant liver fibrosis that
predicts the onset of liver dysfunction, the process being enhanced
by cyclophosphamide (Geraci et al, 1992). In humans, 30Gy can
safely be given to the liver, and even higher radiation doses are
tolerated, if only parts of the liver are irradiated (Dawson et al,
2001). However, as in the animal experiments, cytostatic drugs
may act as radiosensitisers. The relatively high percentage of
causes of death related to the liver or its excretory system (eight of
14) may thus be a consequence of irradiation-induced fibrotic
changes in the upper retroperitoneal space. The two deaths due to
cholelithiasis (according to the certificate of death) may prove to
represent erroneous diagnoses, established at times when compu-
ter tomography (CT) was not available. Computer tomography
would possibly have shown fibrotic changes in the upper
abdomen, leading to chronic stenosis of the bile duct system.
Whether the mortality rate of benign gastrointestinal complication
is reduced by modern radiotherapy (reduced target doses, more
limited fields) has to be proven by forthcoming analyses.
Table 1 Standard mortality ratio and absolute excess risk (per 10000 person years) for patients with malignant germ cell tumours (The Norwegian
Cancer Registry, 1962–1993)
ICD-9 NCR-1 1962–1969 NCR-2 1970–1979 NCR-3 1980–1997 Total 1962–1997
# of patients 570 870 1938 3378
# Person years 9330 12768 19862 41960
Disease of the circulatory system 390–458 OBS 50 40 17 107
EXP 42.5 31 14 88.4
SMR 1.2 (0.9,1.6)
a 1.3 (0.9,1.8) 1.1 (0.7,1.8) 1.2 (1.0,1.5)
AER 8.0 ( 5.7,24.5) 7.0 ( 1.9,18.4) 1.5 ( 2.1,6.6) 4.5 ( 0.4,9.3)
Myocardial infarction 410–414 OBS 35 20 14 69
EXP 29.6 22.1 10.5 62.2
SMR 1.2 (0.8,1.6) 0.9 (0.6,1.4) 1.3 (0.7,2.2) 1.1 (0.9,1.4)
AER 5.7 ( 5.5,20.5)  1.6 ( 7.8,6.8) 1.8 ( 1.4,6.6) 1.6 ( 2.0,6.0)
Gastrointestinal disorders 520–577 OBS 3 7 4 14
EXP 2.6 2.4 1.8 6.7
SMR 1.2 (0.2,3.4) 3.0 (1.2,6.1) 2.2 (0.6,5.8) 2.1 (1.1,3.5)
AER 0.4 ( 2.2,6.6) 3.6 (0.3,9.4) 1.1 ( 0.4,4.3) 1.8 (0.2,4.0)
Accidents, poisoning, suicide 800–999 OBS 11 9 14 34
EXP 10.1 12.7 17.3 40.1
SMR 1.1 (0.5,2.0) 0.7 (0.3,1.3) 0.8 (0.4,1.4) 0.8 (0.6,1.2)
AER 1.0 ( 5.0,10.3)  2.9 ( 6.8,3.5) 1.7 ( 4.8,3.1)  1.4 ( 3.9,1.8)
Nongerm cell cancer 140–239 minus 186 OBS 32 56 28 116
EXP 24.9 20.2 11.8 56.9
SMR 1.3 (0.9,1.8) 2.8 (2.1,3.6) 2.4 (1.6,3.4) 2.0 (1.7,2.4)
AER 7.6 ( 3.4,21.8) 28.0 (17.3,41.1) 8.2 (3.4,14.4) 14.1 (9.0,19.1)
Stomach cancer 151 OBS 2 9 2 13
EXP 2.1 1.5 0.8 4.4
SMR 1.0 (0.1,3.4) 5.9 (2.7,11.3) 2.5 (0.3,9.1) 3.0 (1.6,5.0)
AER  0.1 ( 2.1,5.5) 5.8 (2.00,12.2) 0.6 ( 0.3,3.3) 2.1 (0.6,4.2)
Pancreatic cancer 157 OBS 4 3 2 9
EXP 1.4 1.1 0.6 3.1
SMR 2.8 (0.8,7.1) 2.7 (0.6,7.8) 3.3 (0.4,11.9) 2.9 (1.,5.4)
AER 2.8 ( 0.3,9.4) 1.5 ( 0.4,6.0) 0.7 ( 0.2,3.3) 1.4 (0.2,3.4)
Lung cancer 162 OBS 7 11 6 24
EXP 6.0 5.0 2.6 14
SMR 1.2 (0.5,2.4) 2.2 (1.1,4.0) 2.3 (0.8,4.9) 1.7 (1.1,2.6)
AER 1.1 ( 3.5,9.0) 4.7 (0.4,11.5) 2.0 ( 0.2,5.3) 2.3 (0.3,5.2)
OBS¼observed number; EXP¼expected number; SMR¼standardiszed mortality ratio; AER¼absolute excess risk.
a95% confidence interval.
Increased mortality rates in patients with MGCT
SD Fossa ˚ et al
610
British Journal of Cancer (2004) 90(3), 607–612 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lAs expected, the overall mortality rate due to second nongerm
cell cancer was high, in patients from the NCR-2 group, whereas
radiotherapy alone (NCR-1 group) was not followed by an
increased SMR for second cancer. The significantly increased
SMR of 2.4 in NCR-3 group may in part be due to the continuous
use of combined chemo-radiotherapy in some patients with
advanced seminoma, a strategy that was first discontinued from
1985 onwards. At present, the continuously increased SMR due to
second cancer after 1980 in spite of simultaneous reduction of
radiotherapy warrants the oncologist’s awareness and some
reluctance to use chemotherapy if not absolutely necessary
for cure. It is well known that high-dose cisplatin-based
chemotherapy may increase the risk of secondary leukaemia
(Travis et al, 2000). However, all 28 deaths in the NCR-3 group
were due to solid malignancies. This observation warrants that
patients cured from MGCT by chemotherapy, especially if they also
have received radiotherapy, should have a life-long follow-up with
the aim to diagnose a second cancer as early as possible.
Furthermore, the risk of a second cancer should always be
considered if an individual long-term survivor after successful
treatment of MGCT experiences new and unexpected health
problems.
One important weakness of our study has to be discussed: We
have no individual treatment data as the information on primary
and, in particular, secondary therapy of MGCT is incomplete in the
NCR. The allocation to time periods as done in the present paper
yields the best surrogate estimation of treatment of MGCT
available for us in this population-based series.
In summary, MGCT survivors have a significantly increased risk
of dying from diseases of the circulatory system, benign
gastrointestinal disorders and second nongerm cell cancer. After
the introduction of cisplatin into the treatment of MGCT, the death
rate from diseases of the circulatory disease has, however, not
increased as compared to the preceding decade, when metastatic
patients had been treated with extended radiotherapy, increasingly
combined with noncisplatin containing radiotherapy. Radiother-
apy, in particular, if combined with chemotherapy, generally seems
to increase the death rate of second nongerm cell cancer and also
seems to contribute to the death rate from benign gastrointestinal
disorders.
Further comparative studies in patients treated by either surgery
alone, radiotherapy alone or chemotherapy are urgently needed to
define the risk of serious long-term toxicity after modern
treatment of patients with MGCT.
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